Who
Adam D. Levy
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Acrivon Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 1
- Sells
- 1
- Bought
- $30K
- Sold
- $3,586
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Apr 2025
- Last trade
- 4 Aug 2026
- Last filed
- 6 Aug 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 6 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,7931,142 at $1.57 | filing |
| 4 Aug 2026filed 6 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,7931,142 at $1.57 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,167 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,167 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,925 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,925 at $0.00 | filing |
| 14 Jan 2026filed 16 Jan 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K8,832 at $1.70 | filing |
| 14 Jan 2026filed 16 Jan 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K8,832 at $1.70 | filing |
| 1 Aug 2025filed 5 Aug 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,4671,164 at $1.26 | filing |
| 1 Apr 2025filed 3 Apr 2025 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,209 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.